Deviation – Page 151

Microbial Limits Failure at accelerated stability: GMP documentation for FDA/EMA/MHRA review

Addressing Microbial Limits Failures during Accelerated Stability Testing In pharmaceutical manufacturing, microbial limits failures during accelerated stability testing represent a critical compliance issue with significant implications for product quality and…

Post-Approval Change Failure for innovative delivery systems: risk assessment and validation impact analysis

Analyzing the Impacts of Post-Approval Change Failures in Innovative Delivery Systems In the pharmaceutical manufacturing landscape, ensuring the efficacy and safety of innovative drug delivery systems post-approval is paramount. However,…

Control Strategy Weakness for modified release platforms: risk assessment and validation impact analysis

Addressing Control Strategy Weaknesses for Modified Release Platforms: A Comprehensive Investigation In the world of pharmaceutical manufacturing, particularly for modified release platforms, control strategy weaknesses can lead to significant quality…

Data Integrity Risk during lifecycle management: how to document for FDA/EMA/MHRA review

Managing Data Integrity Risks Throughout the Lifecycle: Documentation for Regulatory Review Data integrity remains a critical concern for pharmaceutical manufacturers, particularly during lifecycle management. The challenge often manifests as deviations,…

API water content (KF) OOS during FDA inspection readiness: how to justify reprocessing vs rejection to FDA/EMA inspectors

Handling OOS Results for API Water Content During FDA Inspection Readiness In the high-stakes world of pharmaceutical manufacturing, encountering Out-Of-Specification (OOS) results during routine checks is a critical issue that…

Sedimentation Oos in ear drop manufacturing: sanitation, water, and EM checks

Investigating the Causes and Solutions of Sedimentation OOS in Ear Drop Manufacturing In the highly regulated environment of pharmaceutical manufacturing, deviations, out-of-specification (OOS) results, and complaints must be investigated thoroughly…

Oos Release Profile for long-acting injectables: how to document for FDA/EMA/MHRA review

Documenting OOS Release Profiles for Long-Acting Injectables: Best Practices for Regulatory Review In the pharmaceutical manufacturing landscape, deviations from expected operational standards can profoundly impact product viability, particularly for long-acting…

Stability Failure after formulation change: control strategy build-out for inspections

Addressing Stability Failures Following Formulation Changes: An Investigation Framework In pharmaceutical manufacturing, formulation changes can lead to unexpected stability failures, prompting deviations or out-of-specification (OOS) results. Such incidents are critical…

API heavy metals / elemental impurities OOS after re-crystallization parameter adjustment: supplier qualification gaps and incoming testing upgrades to close the loop

Investigating OOS Results of API Heavy Metals After Re-crystallization Parameter Adjustments In pharmaceutical manufacturing, the identification of Out-of-Specification (OOS) results regarding heavy metals or elemental impurities post-re-crystallization presents significant compliance…

Phase Separation during method transfer: investigation steps with CAPA evidence

Investigating Phase Separation during Method Transfer: Effective Investigation Steps and CAPA Solutions Phase separation occurring during method transfer is a vital issue that can compromise product integrity in pharmaceutical manufacturing,…

Scale-Up Failure for long-acting injectables: risk assessment and validation impact analysis

Addressing Scale-Up Failure in Long-Acting Injectables: A Comprehensive Investigation Approach Scale-up failures in the manufacturing of long-acting injectables can lead to significant deviations from expected performance, impacting product quality and…

Ivivc Mismatch during PAI readiness: regulatory-ready investigation and CAPA plan

Understanding Ivivc Mismatch during PAI Readiness: A Comprehensive Investigation Approach In the intricate landscape of pharmaceutical manufacturing, ensuring that in vitro-in vivo correlation (IVIVC) aligns during Pharmacokinetic Assessment for submission…